Recent Moves in AtriCure Stock

AtriCure (ATRC) has drawn attention after a recent stretch of positive returns over the past month and past 3 months, prompting investors to reassess how the stock currently prices its medical device business.

Viewed over a longer stretch, AtriCure’s recent 30 day share price return of 19.81% and 90 day share price return of 24.88% sit against a year to date share price decline of 12.13% and a 1 year total shareholder return of 17.48%. This suggests that momentum has been rebuilding after earlier weakness.

If you are looking beyond AtriCure for other healthcare opportunities tied to advanced procedures and technology, it is worth checking out 39 healthcare AI stocks.

Bulls argue AtriCure’s recent rebound reflects growing confidence in its cardiac device platform, while bears point to ongoing losses and a modest value score of 3. Which side does the current valuation support?

Most Popular Narrative: 26.6% Undervalued

The most followed narrative on AtriCure currently pegs fair value at $47.00 versus the last close of $34.51, framing the stock as meaningfully below that central estimate while hinging on a clear growth and profitability roadmap.

Rapid revenue growth is supported by accelerated adoption of AtriCure's innovative, minimally invasive devices like the AtriClip FLEX Mini and cryoSPHERE MAX which directly benefit from the global trend toward minimally invasive cardiac procedures and hospital prioritization of advanced surgical solutions, this increases both volumes and average selling prices, driving top-line expansion.

Want to see how this growth story is built? Revenue, margins and earnings are all tightly mapped to that $47.00 fair value. The key details sit inside the full narrative.

The narrative applies a 7.53% discount rate and leans on compounding revenue growth, improving profit margins and a higher future earnings multiple to bridge the gap between $34.51 and $47.00, so reviewing those underlying assumptions is essential before deciding whether they align with your own expectations.

Result: Fair Value of $47.00 (UNDERVALUED)

However, AtriCure’s story could shift if pulsed field ablation gains faster traction against its ablation devices, or if new left atrial appendage rivals pressure pricing.

Another View: AtriCure Through the SWS DCF Model

The earlier fair value of $47.00 for AtriCure leans on earnings and multiples, but the SWS DCF model paints a very different picture, with an estimated future cash flow value of just $0.75 per share. This suggests the stock screens as significantly overvalued on this method. Which framework sits closer to how you think about risk and return?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across AtriCure’s valuation narratives, now is a good time to review the data yourself and decide what truly matters for you as an investor. You can start with the balance of 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond AtriCure?

If AtriCure has you rethinking your watchlist, do not stop here. Broaden your opportunity set with other stocks that fit clear, data backed filters.

• Target stability and income by reviewing companies in the 9 dividend fortresses that may suit investors who want yield with a focus on resilience.
• Hunt for quality at a potential discount by scanning the 50 high quality undervalued stocks and spotting stocks that combine fundamentals with pricing that may look appealing.
• Spot potential future leaders early by checking the screener containing 20 high quality undiscovered gems before others catch on to their financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.